新型去氟（6）喹诺酮DX-619的体外抗厌氧活性
In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.
作者信息
Tanaka Kaori, Mikamo Hiroshige, Nakao Ken'ichi, Watanabe Kunitomo
机构信息
Division of Anaerobe Research, Life Science Research Center, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan.
出版信息
Antimicrob Agents Chemother. 2006 Nov;50(11):3908-13. doi: 10.1128/AAC.00639-06.
Abstract
The in vitro activity of DX-619, a new des-F(6) quinolone, against anaerobic bacteria was evaluated. DX-619 showed potent activity against Bacteroides, Prevotella, Fusobacterium, Micromonas, Actinomyces, and Clostridium spp., with MIC(50)s/MIC(90)s of </=0.03 to 0.25/</=0.03 to 1 microg/ml, respectively. DX-619 was also active against imipenem-resistant Bacteroides spp., with MIC(50)s/MIC(90)s of 0.25/1 microg/ml, respectively.
摘要
对新型去氟（6）喹诺酮类药物DX - 619针对厌氧菌的体外活性进行了评估。DX - 619对拟杆菌属、普雷沃菌属、梭杆菌属、微小单胞菌属、放线菌属和梭菌属表现出强效活性，其MIC50/MIC90分别≤0.03至0.25/≤0.03至1微克/毫升。DX - 619对耐亚胺培南的拟杆菌属也有活性，其MIC50/MIC90分别为0.25/1微克/毫升。
相似文献
1
In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.新型去氟（6）喹诺酮DX-619的体外抗厌氧活性
Antimicrob Agents Chemother. 2006 Nov;50(11):3908-13. doi: 10.1128/AAC.00639-06.
2
In vitro activity of imipenem against gram-positive anaerobic bacteria.亚胺培南对革兰氏阳性厌氧菌的体外活性。
Int J Clin Pharmacol Res. 1987;7(1):39-43.
3
["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].十种抗菌药物对厌氧菌的“体外”活性。一项合作研究，1999 - 2002年
Rev Argent Microbiol. 2004 Jul-Sep;36(3):130-5.
4
The growth-inhibitory properties of meropenem against anaerobes of clinical importance.美罗培南对具有临床重要性厌氧菌的生长抑制特性。
J Antimicrob Chemother. 1989 Sep;24 Suppl A:119-24. doi: 10.1093/jac/24.suppl_a.119.
5
6
Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.对包括厄他培南在内的七种抗菌药物针对希腊近期分离出的革兰氏阴性厌氧菌的体外活性进行的多中心调查。
Clin Microbiol Infect. 2005 Oct;11(10):820-4. doi: 10.1111/j.1469-0691.2005.01233.x.
7
In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.DX-619及四种对照药物对376株厌氧细菌分离株的体外活性。
Antimicrob Agents Chemother. 2006 May;50(5):1887-9. doi: 10.1128/AAC.50.5.1887-1889.2006.
8
The comparative activity of twelve 4-quinolone antimicrobials against gram-positive and gram-negative anaerobes.
Drugs Exp Clin Res. 1985;11(7):431-4.
9
Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria.ABT-773对362株厌氧菌临床分离株的体外活性比较
Antimicrob Agents Chemother. 2001 Jan;45(1):345-8. doi: 10.1128/AAC.45.1.345-348.2001.
10
In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria.BAY y 3118及其他九种抗菌剂对厌氧菌的体外活性。
J Chemother. 1995 Jun;7(3):189-96. doi: 10.1179/joc.1995.7.3.189.
引用本文的文献
1
Persistent microbial dysbiosis in preterm premature rupture of membranes from onset until delivery.从胎膜早破发作直至分娩期间持续存在的微生物群落失调。
PeerJ. 2015 Nov 26;3:e1398. doi: 10.7717/peerj.1398. eCollection 2015.
2
Bacteroides: the good, the bad, and the nitty-gritty.拟杆菌：有益、有害与关键细节
Clin Microbiol Rev. 2007 Oct;20(4):593-621. doi: 10.1128/CMR.00008-07.
本文引用的文献
1
Anaerobic infections in humans: an overview.人类中的厌氧菌感染：概述
Anaerobe. 1995 Feb;1(1):3-9. doi: 10.1016/s1075-9964(95)80340-8.
2
In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.DX-619及四种对照药物对376株厌氧细菌分离株的体外活性。
Antimicrob Agents Chemother. 2006 May;50(5):1887-9. doi: 10.1128/AAC.50.5.1887-1889.2006.
3
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.艰难梭菌相关性腹泻的多机构主要克隆性暴发，发病率和死亡率高。
N Engl J Med. 2005 Dec 8;353(23):2442-9. doi: 10.1056/NEJMoa051639. Epub 2005 Dec 1.
4
How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?我们应如何应对艰难梭菌的高毒力NAP1/核糖型027菌株？
CMAJ. 2005 Oct 25;173(9):1049-50. doi: 10.1503/cmaj.051212.
5
Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.氟喹诺酮类药物成为艰难梭菌相关性腹泻的主要危险因素：魁北克一次疫情期间的队列研究。
Clin Infect Dis. 2005 Nov 1;41(9):1254-60. doi: 10.1086/496986. Epub 2005 Sep 20.
6
Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.新型去F(6)-喹诺酮类药物DX-619与其他药物相比的抗葡萄球菌活性。
Antimicrob Agents Chemother. 2005 Aug;49(8):3325-33. doi: 10.1128/AAC.49.8.3325-3333.2005.
7
In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.新型去氟（6）喹诺酮DX-619的体外抗菌活性
Antimicrob Agents Chemother. 2005 Jul;49(7):3040-5. doi: 10.1128/AAC.49.7.3040-3045.2005.
8
Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.1991年至2003年魁北克某地区艰难梭菌相关性腹泻：疾病严重程度的变化模式
CMAJ. 2004 Aug 31;171(5):466-72. doi: 10.1503/cmaj.1041104.
9
Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.长期护理机构中艰难梭菌感染的暴发：与加替沙星使用的关联
Clin Infect Dis. 2004 Mar 1;38(5):640-5. doi: 10.1086/381551. Epub 2004 Feb 11.
10
In vitro activities of newer quinolones against bacteroides group organisms.新型喹诺酮类药物对拟杆菌属微生物的体外活性。
Antimicrob Agents Chemother. 2002 Oct;46(10):3276-9. doi: 10.1128/AAC.46.10.3276-3279.2002.
Zotero 插件